Nodulation and nitrogen fixation of some wild legumes from differing habitats in Egypt

This study was devoted to exploring the natural nodulation and nitrogen fixation of wild legumes grown in different Egyptian habitats. These habitats are representative to four phytogeographical regions. Sites that inhabited by Melilotus indicus, Medicago polymorpha, Trifolium resupinatum, Trigonella hamosa and Vicia sativa in each region were selected for study. High nodulation, nitrogen fixation and plant biomass were recorded in plants grown at Nile region and Oases compared with those at Mediterranean region and Sinai. The inhibition in nodulation and potential of nitrogen fixation in legumes at MR and S were attributed to drought and low soil fertility. Differences in species, regions or their interaction have significant effect on nodulation, legheamoglobin, nitroginase activity and biomass of nodules, shoots and roots; the magnitude of effect due to different species was the greatest. Five rhizobial isolates (Sinorhizobium fredii, Rhizobium mesosinicum, Rhizobium daejeonense, Rhizobium huautlense, Rhizobium alamii) recovered from root nodules of the five species were identified by 16S rRNA gene sequence. The indigenous rhizobia of legumes grown at MR and S expected to be exhibit higher tolerance to the existing harsh environmental conditions. These rhizobia can be used as inoculants for crop legumes under unfavorable environmental conditions of agroecosystems or recently reclaimed desert. DOI: http://dx.doi.org/10.5281/zenodo.22401

Hearing Loss After COVID-19 Vaccines: A Systematic Review and Meta-Analysis

ABSTRACT. Background: Hearing loss is generally classified as conductive hearing loss (CHL) and sensory-neural hearing loss (SNHL). It has been reported that COVID-19 infection may affect the vestibular-hearing system causing dizziness, tinnitus, vertigo, and hearing impairment. However, other studies reported that COVID-19 did not lead to significant hearing impairment. Many studies in the literature have reported hearing loss as a complication of COVID-19 vaccines. However, no systematic review or meta-analysis summarizes the literature on this topic.   Method: We performed a comprehensive search for the following databases: PubMed, Cochrane (Medline), Web of Science, and Scopus. All studies published in English till October 2022 were included. These include case reports, case series, prospective and retrospective observational studies, and clinical trials reporting hearing loss following COVID-19 vaccines. Newcastle Ottawa scale (NOS) was used to assess the risk of bias for observational studies. NIH tools were used for non-controlled before and after clinical trials and case reports and case series. A third author solved any disagreements. We analyzed the data using SPSS Software version 26.   Results: A total of 630 patients were identified, with a mean age of 57.3 that ranged from 15 to 93 years old. The majority of the patients were females, 339 (53.8%). In addition, 328 out of 609 vaccinated patients took the Pfizer-BioNTech BNT162b2 vaccine, while 242 (40%) took the Moderna COVID-19 vaccine. The mean time from vaccination to hearing impairment was 6.2, ranging from a few hours to one month after the last dose. Most patients reported unilateral sensorineural hearing loss post-vaccination 593 (94.1%). In order to report the fate of cases, a follow-up was initiated with a mean of 15.6 and a range of 2 to 63 days after the initiation of the treatment. A total of 20 patients were fully recovered, and 11 reported no response. Three out of 328 patients who took the Pfizer-BioNTech BNT162b2 vaccine fully recovered, while five reported partial recovery. According to the chi-squared test, there is a statistically significant difference between patients in terms of fate and the type of COVID-19 vaccination (P-value = 0.001) while reporting no significant difference in dose number prior to the onset of the symptoms (P-value = 0.65) and gender (P-value = 0.4). The ANOVA test was conducted to compare vaccine types and the number of doses in terms of mean time from vaccination to hearing impairment onset. The results found a significant difference between vaccine types (P-value < 0.000) while showing no significance in terms of the number of doses prior to the onset (P-value = 0.6).   Conclusion: There is a statistically significant difference between patients in terms of fate and the type of COVID-19 vaccination while reporting no significant difference in dose number prior to the onset of the symptoms and gender. Further, we concluded that there is a significant difference between vaccine types while showing no significance in terms of the number of doses prior to the onset

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar.

We investigated what proportion of the population acquired severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and whether the herd immunity threshold has been reached in 10 communities in Qatar. The study included 4,970 participants during June 21-September 9, 2020. Antibodies against SARS-CoV-2 were detected by using an electrochemiluminescence immunoassay. Seropositivity ranged from 54.9% (95% CI 50.2%-59.4%) to 83.8% (95% CI 79.1%-87.7%) across communities and showed a pooled mean of 66.1% (95% CI 61.5%-70.6%). A range of other epidemiologic measures indicated that active infection is rare, with limited if any sustainable infection transmission for clusters to occur. Only 5 infections were ever severe and 1 was critical in these young communities; infection severity rate of 0.2% (95% CI 0.1%-0.4%). Specific communities in Qatar have or nearly reached herd immunity for SARS-CoV-2 infection: 65%-70% of the population has been infected

Non-Linear Optical Property and Biological Assays of Therapeutic Potentials Under In Vitro Conditions of Pd(II), Ag(I) and Cu(II) Complexes of 5-Diethyl amino-2-({2-[(2-hydroxy-Benzylidene)-amino]-phenylimino}-methyl)-phenol

Herein, we report facile procedures for synthesis of a new Schiff base ligand (H2L,5-Diethylamino-2-({2-[(2-hydroxy-benzylidene)-amino]-phenylimino}-methyl)-phenol) and its Ag(I), Pd(II) and Cu(II) complexes. The structure of the H2L ligand as well as its metal complexes was deduced based on wide range of analytical, structural and spectroscopic tools, along with theoretical evidence via density functional theory (DFT) calculations. The obtained results indicated that the Schiff base (H2L) ligand acts as a tetradentate N2O2 donor with two azomethine nitrogen’s (N1, N2) and two deprotonated phenolic oxygens (O1, O2) atoms. A distorted octahedral structure is assigned to [CuL(OH2)2]·3/2H2O complex and square planar structure for PdL and AgL complexes. The electronic structure and non-linear optical (NLO) property of the prepared compounds were discussed theoretically by the B3LYP/GENECP program. Results revealed that all complexes have non-planner geometries as indicated from the dihedral angles. The charge transfer occurs within the synthesized complexes as indicated from the calculated energy gap between HOMO and LUMO energies. The H2L ligand and its complexes are excellent candidates for NLO materials as implied from their hyperpolarizabilities and polarizabilities values. The biological activities of the prepared complexes against selected microorganisms and cancer cell lines gave good growth inhibitory effect. The biocidal potencies of the ligand and its complexes can be arranged as follows: AgL > CuL > PdL > H2L, as compared to the used standard drugs. The antiproliferative activity of the studied complexes against different carcinoma cell lines such as liver (Hep-G2), breast (MCF-7) and colon (HCT-116) followed the order H2L < AgL< PdL < CuL < vinblastine. Probing the binding interactions of prepared complexes with calf thymus (CT)-DNA using electronic absorption, gel electrophoresis and viscosity measurements revealed strong interaction via intercalation modes, as also evidenced by their molecular docking study

Facile synthesis and grafting of N₂O₂-Cu(II) Schiff base complex onto graphene oxide surface: aspects of its antimicrobial, anticancer, antiCOVID-19 and photodegradation of methylene blue

In this study, a facile synthesis and grafting method is reported for tetradentate Cu(II) Schiff base complex onto the surface of graphene oxide (GO). The Schiff base Cu-complex was synthesized through the condensation reaction between 2,3-diamino pyridine and 2-hydroxy-1-naphthaldehyde, followed by the addition of Cu(II) ion to afford N2O2-Cu(II) complex. The GO was prepared through a modified Hummers’ method and characterized using various spectroscopic and microscopic techniques. The Schiff base Cu-complex was then grafted onto the surface of GO via a simple solution-phase reaction, resulting in the formation of N2O2-Cu(II) Schiff base/GO composite. The fabricated composite was characterized using FTIR spectroscopy, UV–vis, X-ray diffraction (XRD), and scanning electron microscopy (SEM). Importantly, the prepared N2O2-Cu(II) Schiff base complex exhibited excellent DNA interaction as well as efficient antimicrobial and anticancer activities. Additionally, it demonstrated potent anticancer activity against hepatocellular carcinoma cells (HepG-2), and colon cancer cells (HCT-116) and exhibited promising activity against the COVID-19 receptor (PDB ID: 6LU7) along with the human DNA receptor (PDB ID: 1BNA). Furthermore, this fabricated heterogeneous catalyst showed enhanced photodegradation of MB with ≈92% conversion and four times recyclability. The overall results suggest that the Cu(II) Schiff base/GO composite has potential applications in various medical and environmental fields, including photodegradation/elimination of harmful organic dyes for water treatment applications.</p

Exploring the Journey of Zinc Oxide Nanoparticles (ZnO-NPs) toward Biomedical Applications

The field of nanotechnology is concerned with the creation and application of materials having a nanoscale spatial dimensioning. Having a considerable surface area to volume ratio, nanoparticles have particularly unique properties. Several chemical and physical strategies have been used to prepare zinc oxide nanoparticles (ZnO-NPs). Still, biological methods using green or natural routes in various underlying substances (e.g., plant extracts, enzymes, and microorganisms) can be more environmentally friendly and cost-effective than chemical and/or physical methods in the long run. ZnO-NPs are now being studied as antibacterial agents in nanoscale and microscale formulations. The purpose of this study is to analyze the prevalent traditional method of generating ZnO-NPs, as well as its harmful side effects, and how it might be addressed utilizing an eco-friendly green approach. The study’s primary focus is on the potential biomedical applications of green synthesized ZnO-NPs. Biocompatibility and biomedical qualities have been improved in green-synthesized ZnO-NPs over their traditionally produced counterparts, making them excellent antibacterial and cancer-fighting drugs. Additionally, these ZnO-NPs are beneficial when combined with the healing processes of wounds and biosensing components to trace small portions of biomarkers linked with various disorders. It has also been discovered that ZnO-NPs can distribute and sense drugs. Green-synthesized ZnO-NPs are compared to traditionally synthesized ones in this review, which shows that they have outstanding potential as a potent biological agent, as well as related hazardous properties

A Literature review of traumatic brain injury biomarkers

Research into TBI biomarkers has accelerated rapidly in the past decade owing to the heterogeneous nature of TBI pathologies  and management, which pose challenges to TBI evaluation, management, and prognosis. TBI biomarker proteins resulting  from axonal, neuronal, or glial cell injuries are widely used and have been extensively studied. However, they might not pass  the blood-brain barrier with sufcient amounts to be detected in peripheral blood specimens, and further might not be detectable in the cerebrospinal fuid owing to fow limitations triggered by the injury itself. Despite the advances in TBI research,  there is an unmet clinical need to develop and identify novel TBI biomarkers that entirely correlate with TBI pathologies on  the molecular level, including mild TBI, and further enable physicians to predict patient outcomes and allow researchers to  test neuroprotective agents to limit the extents of injury. Although the extracellular vesicles have been identifed and studied  long ago, they have recently been revisited and repurposed as potential TBI biomarkers that overcome the many limitations  of the traditional blood and CSF assays. Animal and human experiments demonstrated the accuracy of several types of  exosomes and miRNAs in detecting mild, moderate, and severe TBI. In this paper, we provide a comprehensive review of  the traditional TBI biomarkers that are helpful in clinical practice. Also, we highlight the emerging roles of exosomes and  miRNA being the promising candidates under investigation of current research. </p

Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint

Breast cancer (BrCa) is the most common malignancy in women and the second most significant cause of death from cancer. BrCa is one of the most challenging malignancies to treat, and it accounts for a large percentage of cancer-related deaths. The number of cases requiring more effective BrCa therapy has increased dramatically. Scientists are looking for more productive agents, such as organic combinations, for BrCa prevention and treatment because most chemotherapeutic agents are linked to cancer metastasis, the resistance of the drugs, and side effects. Natural compounds produced by living organisms promote apoptosis and inhibit metastasis, slowing the spread of cancer. As a result, these compounds may delay the spread of BrCa, enhancing survival rates and reducing the number of deaths caused by BrCa. Several natural compounds inhibit BrCa production while lowering cancer cell proliferation and triggering cell death. Natural compounds, in addition to therapeutic approaches, are efficient and potential agents for treating BrCa. This review highlights the natural compounds demonstrated in various studies to have anticancer properties in BrCa cells. Future research into biological anti-BrCa agents may pave the way for a new era in BrCa treatment, with natural anti-BrCa drugs playing a key role in improving BrCa patient survival rates

Health economics: direct cost of osteoporotic hip fracture in Egypt—an analysis for the Egyptian healthcare system by the Egyptian Academy of Bone Health

Abstract Mini abstract This work studies the direct cost of hip fractures in Egypt. The direct cost was calculated based on the incidence of hip fracture in Egypt retrieved from the national database. The result of this work raises red flags to the policy makers in Egypt that such fragility fractures are preventable, should appropriate approaches be implemented. Background This study provides an analysis for the healthcare system in Egypt. It was carried out to assess the direct annual cost incurred to the Egyptian healthcare system in 2023 as a result of fragility hip fractures in older adult Egyptians. Results The direct costs of hip fractures incurred during the first year after the injury were estimated at 1,969,385,000 Egyptian pounds (US $63,734,142.4). Time from fracture to surgery was 2.2 + 0.5 days. The average hospital stay after hip fracture surgery was 5.2 + 2.6 days. 4.5% of patients died after surgery, on average 2.3 + 0.4 months. After being discharged from the hospital, all patients needed home care. Conclusion Hip fractures have a significant clinical and financial impact on patients and the healthcare system. This study raises red flags for the healthcare policy makers in Egypt, as the financial burden due to the direct costs of hip fractures justifies extensive prevention programs for osteoporosis and fragility fractures. There is an urgent need to implement diagnostic approaches and validated management protocols for bone health disorders and its associated fractures in Egypt

A Comprehensive In Silico Study of New Metabolites from Heteroxenia fuscescens with SARS-CoV-2 Inhibitory Activity

Chemical investigation of the total extract of the Egyptian soft coral Heteroxenia fuscescens, led to the isolation of eight compounds, including two new metabolites, sesquiterpene fusceterpene A (1) and a sterol fuscesterol A (4), along with six known compounds. The structures of 1&ndash;8 were elucidated via intensive studies of their 1D, 2D-NMR, and HR-MS analyses, as well as a comparison of their spectral data with those mentioned in the literature. Subsequent comprehensive in-silico-based investigations against almost all viral proteins, including those of the new variants, e.g., Omicron, revealed the most probable target for these isolated compounds, which was found to be Mpro. Additionally, the dynamic modes of interaction of the putatively active compounds were highlighted, depending on 50-ns-long MDS. In conclusion, the structural information provided in the current investigation highlights the antiviral potential of H. fuscescens metabolites with 3&beta;,5&alpha;,6&beta;-trihydroxy steroids with different nuclei against SARS-CoV-2, including newly widespread variants